Rutgers Cancer Institute, along with its partner RWJBarnabas Health, offers the most advanced cancer treatment options including clinical trials and novel therapeutics such as precision medicine and immunotherapy.

Your link to the latest news on research, treatment, prevention and education from the state's only

National Cancer Institute-designated Comprehensive Cancer Center

Creating a Precision Paradigm

Investigators working on the precision medicine initiative at The Cancer Institute of New Jersey are embarking on a genomic analysis study that could illuminate more options in developing personalized therapies for cancer patients. It is believed that some rare and poor prognosis cancers may harbor genomic changes that can potentially be treated with specific targeted therapies. Through Next Generation Sequencing and data analysis of DNA in tissue samples, researchers aim to identify these changes in order to guide treatment.Learn more

Research from The Cancer Institute of New Jersey led by Isaac Kim, MD, PhD, suggests more stringent criteria may be needed for African-American men with prostate cancer when considering active monitoring of the disease. Prevalence of advanced stage cancer in African-American men considered to have low-risk prostate cancer on initial consultation but chose to undergo radical prostatectomy was found to be nearly twice that of Caucasian men. The findings suggest the definition of low-risk prostate cancer should not be the same for these two groups of men.Learn more

Pharmacy Expertise Expands at The Cancer Institute of New Jersey

One of the hallmarks of a National Cancer Institute-designated Comprehensive Cancer Center like The Cancer Institute of New Jersey, is the unique oncology expertise exhibited by its clinical team - including pharmacists. The Cancer Institute demonstrates this excellence by having four pharmacists certified as Board Certified Oncology Pharmacists (BCOP). The BCOP certification is held by only 1,095 pharmacists in the nation - the highest concentration of which (29) are from New Jersey.Learn more

Recognized for Research Excellence

Two world-renowned researchers at The Cancer Institute of New Jersey are being recognized by the American Association for Cancer Research (AACR), the world's largest professional organization dedicated to advancing cancer research. Chief Scientific Officer Joseph R. Bertino, MD, and Resident Member Arnold J. Levine, PhD are being honored as part of the inaugural class of fellows in the AACR Academy. Also being recognized as part of this prestigious group is William N. Hait, MD, PhD, founding director of The Cancer Institute of New Jersey.Learn more

Cigarette Relighting Tied to Tough Economy

In what is believed to be a first of its kind study, Michael Steinberg, MD, MPH, a member of The Cancer Institute of New Jersey and Director of the Tobacco Dependence Program, and colleagues have found that an accelerating trend of smokers relighting cigarettes is related to economic factors. The practice has implications for tobacco dependence treatment and policy. Higher rates of relighting were found among females, African-Americans and smokers who are divorced, widowed or separated. Other related factors include being sick or disabled, or having a high school degree or less.Learn more